BioSpace News Archive

With a mission to lessen the impact of cancer on families, Ontario-based Nanny Angel Network was named the $100,000 grand prize winner of the Astellas Oncology Changing Cancer Care (C3) Prize.

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders that Alfasigma S.p.A (“Alfasigma”), the licensee of Brilacidin for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), is targeting mid-year 2020 to commence clinical trials of Brilacidin for the UP/UPS indication.

The RECOVER™ study is assessing real-world, patient-centered outcomes including abstinence from illicit opioids and life changes, such as improved health, employment status and connection to community following treatment with SUBLOCADE™ (Buprenorphine Extended-Release) Injection.

A-Medicare Vision is to Remake Healthcare in the United States through a competitive high-tech services portal and broad public-private sector interface.

VistaGen’s PH94B is the first drug candidate to be granted U.S. FDA Fast Track designation for treatment of social anxiety disorder

Researchers at Columbia University Discover Link Between Opioid Overdose and Treatment with Buprenorphine.

The NCCN Oncology Research Program will oversee academic/community projects that explore how different health systems can work together to enhance treatment quality for advanced breast cancer patients.

U.S. Food and Drug Administration (FDA) has granted Fast Track designation for lebrikizumab, its novel, investigational treatment being evaluated for patients with moderate-to-severe atopic dermatitis.

New Teledermatology Service Designed to Provide Quick Diagnosis and Treatment to Patients with Psoriasis, Vitiligo or Eczema

New integration allows Epic users to send text messages during care